MENU
+Compare
TRVI
Stock ticker: NASDAQ
AS OF
Apr 24, 01:19 PM (EDT)
Price
$6.34
Change
+$0.07 (+1.12%)
Capitalization
586.86M

TRVI Trevi Therapeutics Forecast, Technical & Fundamental Analysis

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis... Show more

TRVI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for TRVI with price predictions
Apr 23, 2025

Momentum Indicator for TRVI turns positive, indicating new upward trend

TRVI saw its Momentum Indicator move above the 0 level on April 22, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 91 similar instances where the indicator turned positive. In of the 91 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where TRVI advanced for three days, in of 267 cases, the price rose further within the following month. The odds of a continued upward trend are .

TRVI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The 10-day RSI Indicator for TRVI moved out of overbought territory on March 21, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Moving Average Convergence Divergence Histogram (MACD) for TRVI turned negative on March 27, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TRVI declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for TRVI entered a downward trend on April 22, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. TRVI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.083) is normal, around the industry mean (14.056). P/E Ratio (0.000) is within average values for comparable stocks, (63.446). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.788). Dividend Yield (0.000) settles around the average of (0.025) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (252.992).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
TRVI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

TRVI is expected to report earnings to rise 21.64% to -13 cents per share on May 08

Trevi Therapeutics TRVI Stock Earnings Reports
Q1'25
Est.
$-0.13
Q4'24
Beat
by $0.01
Q3'24
Missed
by $0.01
Q2'24
Missed
by $0.01
Q1'24
Missed
by $0.02
The last earnings report on March 18 showed earnings per share of -10 cents, beating the estimate of -11 cents. With 98.60K shares outstanding, the current market capitalization sits at 586.86M.
A.I. Advisor
published General Information

General Information

a developer and manufacturer of neurological products

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
195 Church Street
Phone
+1 203 304-2499
Employees
25
Web
https://www.trevitherapeutics.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ARRRX14.28N/A
N/A
AB Global Real Estate Investment R
FICEX13.43N/A
N/A
Frost Growth Equity Inst
PCGRX21.34N/A
N/A
Victory Pioneer Mid Cap Value A
LAVSX14.02N/A
N/A
Lord Abbett Fundamental Equity R4
SVALX5.99N/A
N/A
Federated Hermes Strategic Value Div R6

TRVI and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, TRVI has been loosely correlated with PTGX. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if TRVI jumps, then PTGX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TRVI
1D Price
Change %
TRVI100%
+3.29%
PTGX - TRVI
43%
Loosely correlated
+0.72%
CKPT - TRVI
34%
Loosely correlated
N/A
MLYS - TRVI
31%
Poorly correlated
+2.42%
AURA - TRVI
31%
Poorly correlated
+0.88%
QURE - TRVI
30%
Poorly correlated
N/A
More